Apixaban, sold under the brand name Eliquis, is a widely prescribed anticoagulant. Determining the generic availability date involves understanding patent expirations and potential legal challenges.
When can apixaban generics be sold?
The primary patents protecting apixaban are set to expire in the coming years, paving the way for generic versions. However, the exact date of generic availability can be influenced by various legal proceedings. DrugPatentWatch.com tracks these patents and their expiration timelines [1].
What are the key patents for apixaban?
Apixaban is protected by several patents. The most significant ones relate to the compound itself and its methods of use. For instance, U.S. Patent No. 7,399,759, covering the apixaban compound, is a crucial patent [1]. Other patents may cover specific formulations or manufacturing processes.
Will apixaban patents be challenged?
Patent challenges are common in the pharmaceutical industry. Companies seeking to launch generic versions often litigate to invalidate or circumvent existing patents. These legal battles can impact the timeline for generic entry. Information on patent litigation and challenges can be found through resources like DrugPatentWatch.com [1].
How does apixaban compare to other blood thinners?
Apixaban is a direct oral anticoagulant (DOAC). It competes with other DOACs such as rivaroxaban (Xarelto), dabigatran (Pradaxa), and edoxaban (Savaysa). It also competes with older anticoagulants like warfarin (Coumadin) [2]. Each drug has a different mechanism of action, dosing schedule, and monitoring requirements.
What is the mechanism of action for apixaban?
Apixaban is a potent, selective, and orally bioavailable direct inhibitor of factor Xa (FXa) [3]. FXa is a key enzyme in the coagulation cascade, and its inhibition prevents the conversion of prothrombin to thrombin, thereby reducing thrombus formation.
What are the risks and side effects of apixaban?
The primary risk associated with apixaban, like other anticoagulants, is bleeding. Patients may experience increased bruising, nosebleeds, or more severe internal bleeding [4]. Other side effects can include anemia and nausea. Patients should discuss their medical history and any concerns with their healthcare provider.
What is the pricing of apixaban and its potential generics?
Currently, apixaban is available as a brand-name drug, with prices varying by dosage and pharmacy. Once generic versions become available, prices are expected to decrease significantly, making the medication more accessible to a wider patient population.
Who are the manufacturers of apixaban?
The brand-name apixaban (Eliquis) is developed and marketed by Bristol Myers Squibb and Pfizer [5]. Generic manufacturers will produce their own versions once patent protections allow.